Sangamo Therapeutics (NASDAQ:SGMO) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight ...
Q4 2025. Management View. CEO Alexander Macrae stated that "Sangamo continued to make significant pipeline progress in 2025 and ...
3h
China Leading LiFePO4 Battery Manufacturer Lithmate: 16 Years, 100+ Patents, 100+ Countries Served
HUIZHOU, GUANGDONG, CHINA, March 31, 2026 /EINPresswire.com/ -- As global demand for clean energy accelerates, choosing ...
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across ...
Step inside the AlphaESS factory to see how smart batteries are built and how scalable storage is powering energy ...
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across al ...
BENGALURU: The US Food and Drug Administration has approved a higher dose of Biogen’s spinal muscular atrophy drug Spinraza, ...
23hon MSN
US stocks: Biogen gets FDA approval for higher dose of genetic disorder drug, shares rise 3%
The U.S. Food and Drug Administration has approved a higher dose of Biogen's spinal muscular atrophy drug Spinraza, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results